Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

We examined the long-term effects of everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. Following favorable results from the double-blind core phase of EXIST-2 (NCT00790400), patients were allowed to receive open-label ev...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2017-08, Vol.12 (8), p.e0180939-e0180939
Hauptverfasser:	Bissler, John J, Kingswood, J Chris, Radzikowska, Elzbieta, Zonnenberg, Bernard A, Belousova, Elena, Frost, Michael D, Sauter, Matthias, Brakemeier, Susanne, de Vries, Petrus J, Berkowitz, Noah, Voi, Maurizio, Peyrard, Severine, Budde, Klemens
Format:	Artikel
Sprache:	eng
Schlagworte:	Acne Adolescent Adult Analysis Angiomyolipoma Angiomyolipoma - drug therapy Antineoplastic Agents - therapeutic use Aphthous stomatitis Astrocytoma Astrocytoma - drug therapy Biology and Life Sciences Bleeding Cancer Child & adolescent psychiatry Dosage and administration Drug therapy Embolization Everolimus Everolimus - adverse effects Everolimus - therapeutic use Female Forced Expiratory Volume - drug effects Hospitals Humans Hypercholesterolemia Inhibitor drugs Kidney cancer Kidney transplantation Kidneys Lesions Long-term effects Lung diseases Lymphangioleiomyomatosis - drug therapy Male Medicine and Health Sciences Middle Aged Nephrology NMR Nuclear magnetic resonance Oncology Pain Patients Pediatrics Pharmaceuticals Prospective Studies Reduction Renal function Research and Analysis Methods Response rates Rhinopharyngitis Risk assessment Skin diseases Stomatitis Treatment Outcome Tuberous sclerosis Tuberous Sclerosis - pathology Vital Capacity - drug effects Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!